Stewart Lyman

Stewart Lyman is Owner and Manager of Lyman BioPharma Consulting LLC in Seattle. He provides advice to biotechnology and pharmaceutical companies as well as academic researchers and venture capital firms. Previously, he spent 14 years as a scientist at Immunex prior to its acquisition by Amgen.

Recent posts

Pharma-Academic Alliances: What the Numbers Don’t Tell You

If you’ve been following the drug industry at all for the past few years, you know that Big Pharma has gone alliance crazy.

It seems that every other week a new... Read more »
Why Do I Love Drug Regulation? Simple: It Keeps Us Safe

I frequently read comments from pundits and politicians decrying the US drug regulatory system, specifically the FDA. Many of these people, reading from the same PR playbook, will try to convince... Read more »
Who’s Going to Pay for Future Drug Development? (Part 2)

In the first part of this article, I detailed how pharma and biotech companies, along with the federal government, provide the majority of funding for biomedical research in the U.S.... Read more »
Who’s Going to Pay for Future Drug Development? (Part 1)

In case you haven’t noticed, heart disease remains a debilitating illness for millions. Cancer, despite some recent advances, has not been cured. Drug resistant strains of bacteria are spreading across the... Read more »
Advice Received, But Not Taken: Tales from the Biotech Trenches

Biotechnology is a challenging business, with drug development timelines that are long, costly, and dependent on the approval of government regulatory agencies. The vast majority of biotechs never succeed in developing... Read more »
What Does Biotech Really Suffer From? Information Overload, or Underload?

Cognitive dissonance is defined as “an uncomfortable feeling caused by holding conflicting ideas simultaneously.” I’m suffering from a serious case of discomfort as I try to figure out which is the... Read more »
The Myth of the “Patent Cliff”

Doctors, patients, and investors who follow the biopharmaceutical business all recognize that the industry is exceedingly complex and in the midst of change. Companies struggle daily with a multifaceted mix of... Read more »
The Winners of the IRS Biotech Grant Program Are…

[Updated: 11:30 am, 11/4/10] The biotech industry was a key beneficiary last spring of the new health care law. $1 billion worth of Qualifying Therapeutic Discovery Project Credits were... Read more »
The Challenge of Understanding Biotech: Sifting Through the Fog and Jargon

I recently enjoyed reading two books on the mortgage meltdown, “The Big Short” by Michael Lewis and Gregory Zuckerman’s “The Greatest Trade Ever.” They each provided a... Read more »
ZymoGenetics Will Be Missed. How Seattle Biotech Can Recover and Thrive

I agree with Carl Weissman’s recent Xconomy column about the ZymoGenetics acquisition when he says that Seattle needs to be a place where biotech startups thrive. Unfortunately, his column didn’t put... Read more »
Biotech Drug Discovery in Seattle: A Look Back

The drug discovery and development process is a difficult one that takes considerable expertise in both the research and business realms. Seattle currently has approximately 103 biotechnology companies, 21 of... Read more »
Biotech’s $1 Billion Tax Credits Are Up for Grabs! OK, Now Everybody Relax

The rules regarding the Qualifying Therapeutic Discovery Project Credit have now been released by the Treasury Department. You can read the fact sheet, and detailed description of the legislation yourself,... Read more »
Biotech’s Second Big Win in Healthcare Reform: A Tax Credit Bonanza

The biotech industry won a major victory last month when President Obama signed healthcare reform into law. Biologic drugs, those developed through genetic engineering techniques and incubated in living cells, will... Read more »
The Pharmaceutical R&D Model is Broken. Here’s How to Fix It

Research is the lifeblood of the biotech and pharmaceuticals business. The pharma and biotech industry spent some $65 billion dollars on R & D in 2008, according to the Pharmaceutical Research... Read more »
A Brief Year-End Review of Seattle Biotech

Well, 2009 did not turn out to be the biotechnology disaster here in Seattle that many people had predicted.

By my reckoning, only four of the local biotech companies that I... Read more »
Hollywood Sees Corruption in Pharma, and Suddenly Scientists are the Bad Guys

A recent article in the journal Science described a significant gene-therapy based advance in the treatment of two boys with adrenoleukodystrophy (ALD), a rare and lethal genetic disease. This was wonderful... Read more »
“Don’t Touch My Bags If You Please, Mr. Customs Man”

Imagine the following scenario for a minute: A middle-aged man books a round trip ticket from San Francisco to Shanghai. His reservation indicates this will be a short trip; he is... Read more »
Why Big Pharma Wants To Be Like Big Biotech

Why would a Big Pharma company want to remake itself as a biotech? In a recent Xconomy piece, I discussed the changes in Roche’s corporate culture brought on by their recent... Read more »
Forget the Shortcuts: Creating a Truly Innovative Biotech Culture

Watching the acquisition of Genentech by Roche has been a fascinating process. I wasn’t so interested in the eventual price paid per share, but whether Basel, Switzerland-based Roche, one of the... Read more »
Measuring Success in the Biotech World

What defines success in biotechnology? I’ve noticed that many companies are described as being successful, but there’s no widely agreed upon definition for success within the industry. Lack of agreement on... Read more »

Page 2 of 3 « previous page · next page »

Stewart Lyman

Recent posts

Underwriters and Partners

Xconomy Events Across the Network

Connect with Xconomy

Xconomy’s Most Popular

Xconomy on Demand